Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05481775

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Efficacy and Safety Clinical Trial

Official title:
Evaluating Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy Versus Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer: A Prospective, Randomized Controlled Phase II Clinical Trial

Clinical Trial Summary

This is a prospective, randomized, controlled phase II clinical study for evaluating anlotinib combined with concurrent chemoradiotherapy followed by consolidation immunotherapy versus concurrent chemoradiotherapy followed by consolidation immunotherapy in locally advanced, unresectable NSCLC.

Clinical Trial Description

This is a prospective, randomized, controlled phase II clinical study for evaluating anlotinib combined with concurrent chemoradiotherapy followed by consolidation immunotherapy versus concurrent chemoradiotherapy followed by consolidation immunotherapy in locally advanced, unresectable NSCLC. In this study, the enrolled patients were divided into the experimental group and the control group at a ratio of 1:1. The patients in the experimental group received anlotinib combined with curative concurrent chemoradiotherapy first, while the patients in the control group received curative concurrent chemoradiotherapy. Those who are evaluated as CR, PR or SD after the aforementioned treatment will enter consolidation immunotherapy. Patients will receive tislelizumab 200mg iv. drip, Q3W, for up to 12 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05481775
Study type Interventional
Source Sun Yat-sen University
Contact
Status Withdrawn
Phase Phase 2
Start date April 1, 2022
Completion date September 30, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04759534 - Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia Phase 3
Not yet recruiting NCT05532111 - Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial N/A
Active, not recruiting NCT04284215 - Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC N/A
Completed NCT06202456 - A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver Phase 4
Completed NCT04870606 - Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness Phase 3
Completed NCT03660761 - Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors Phase 2
Active, not recruiting NCT03794778 - Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Phase 4
Recruiting NCT03255343 - Treatment of Non-responding to Conventional Therapy Inoperable Liver Cancers by in Situ Introduction of ImDendrim N/A
Recruiting NCT04197544 - Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study. N/A
Recruiting NCT04518501 - Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer Phase 1/Phase 2
Completed NCT03779776 - The Efficacy and Safety of Early Vitamin AD Supplementation in Very Preterm Infants N/A
Not yet recruiting NCT06218004 - Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma Phase 2
Enrolling by invitation NCT02809079 - Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Phase 4
Active, not recruiting NCT06194188 - A Phase 2 Clinical Study of CU-20401 Phase 2
Recruiting NCT03901235 - MSC Intratissular Injection in Crohn Disease Patients Phase 1/Phase 2
Completed NCT03826004 - Clemastine in Cardiovascular Surgery N/A
Active, not recruiting NCT03623776 - Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. Phase 2
Recruiting NCT04078399 - Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence N/A
Not yet recruiting NCT06351735 - Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis
Not yet recruiting NCT06383078 - HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer Phase 2